Expression and clinical significance of PTPRJ in non-small cell lung cancer tissues
BAO Chuanming
FAN Bing
CHEN Can
PENG Junwei
Abstract：Objective To explore the expression level and clinical significance of protein tyrosine phosphatase receptor type J (PTPRJ) in non-small cell lung cancer (NSCLC) tissues.Methods One hundred and twelve cases of NSCLC tissues were collected from January 2014 to December 2017.PTPRJ gene was detected by real-time quantitative polymerase chain reaction (QPCR) in NSCLC tissues with 104 cases of paracancerous tissues as control.According to the average value of PTPRJ mRNA level in cancer tissues, NSCLC patients were divided into low-expression group (＜average value) and high-expression group (≥average value). The expression and distribution of PTPRJ in different clinicopathological features (sex, age, smoking history, tumor size, lymph node metastasis, TNM stage, pathological type and PS score) were analyzed.The median overall survival (OS) of different PTPRJ mRNA levels was compared according to follow-up data.ResultsThe mRNA level of PTPRJ in NSCLC tissues was 0.313±0.149, lower than1.028±0.286 in adjacent tissues (P＜0.05). According to the average value of PTPRJ mRNA, 112 NSCLC tissues was divided into 60cases with low-expression and 52 cases with high-expression.The results showed that PTPRJ mRNA level was dependent with gender, age, pathological type and PS score of NSCLC, but associated with smoking history, lymph node metastasis, tumor size and TNM stage.The levels and high-expression rates of PTPRJ in patients with smoking history, lymph node metastasis, large tumor size (＞3cm) and late stages (stageⅢ) were 0.290±0.128 and 38.0％ (30/79), 0.282±0.158 and 28.6％ (20/70), 0.244±0.099 and26.2％ (17/65), 0.266±0.106 and 29.7％ (11/37), higher than 0.367±0.182 and 66.7％ (22/33), 0.364±0.119 and 76.2％ (32/42), 0.407±0.156 and 74.5％ (35/47) and 0.336±0.162 and 54.7％ (41/75) of patients with without smoking history, lymph node metastasis, small tumor size (＜3 cm) and early stage (Ⅰ-Ⅱ). The follow-up time was 9-36 months (median 25.0months) and the median OS was 34.0 months.The median OS of PTPRJ high-expression was more than 36.0 months, longer than24.0 months of low-expression (P＜0.05). Conclusion Low expression of PTPRJ participates in the occurrence and development of NSCLC and plays a role of tumor suppressor gene.The prognosis of low expression of PTPRJ is poor.This factor is expected to become a potential factor in the diagnosis and predicting of the prognosis of NSCLC.
Keywords：Non-small cell lung cancerProtein tyrosine phosphatase receptor type J (PTPRJ)Clinical significancePrognosis
Publication Date：2018-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 1084-1089 )